Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
100%
Oxaliplatin
65%
Colorectal Carcinoma
44%
Cetuximab
34%
Overall Survival
27%
Chemotherapy
26%
Irinotecan
21%
microRNA
21%
Bevacizumab
21%
Peritoneum Metastasis
21%
Neoplasm
18%
Malignant Neoplasm
17%
Biological Marker
17%
Capecitabine
14%
Epidermal Growth Factor Receptor
12%
Primary Tumor
12%
Pancreas Cancer
11%
Urokinase Receptor
10%
Encorafenib
10%
Tissue Inhibitor of Metalloproteinase
10%
Binimetinib
10%
DNA Topoisomerase
10%
Cross-Sectional Study
10%
Epirubicin
10%
Long Term Survival
10%
Progression Free Survival
8%
Abdominal Cancer
6%
Systemic Treatment
5%
Regorafenib
5%
Trifluridine
5%
Tipiracil
5%
Antiangiogenic
5%
Medicine and Dentistry
Chemotherapy
66%
Metastatic Colorectal Cancer
52%
Peritoneum Metastasis
52%
Colorectal Carcinoma
39%
Oxaliplatin
29%
Pancreas Cancer
22%
Neoplasm
18%
Abdominal Cancer
16%
Biological Marker
15%
Irinotecan
15%
Biopsy Technique
13%
Arm
12%
Cancer Cell
12%
Gene Amplification
10%
Capecitabine
10%
Gastrectomy
10%
Bevacizumab
10%
Epirubicin
10%
Topoisomerase
10%
Recurrent Disease
10%
Pembrolizumab
10%
microRNA
10%
Long Term Survival
10%
Metalloprotease Inhibitor
10%
Ovarian Cancer
10%
Colon Carcinoma
10%
Epidermal Growth Factor Receptor
8%
Immunotherapy
7%
Overall Survival
6%
Adverse Event
6%
Surgery
5%
Cisplatin
5%
Doxorubicin
5%
Regorafenib
5%
Molecular Profiling
5%
Antiangiogenic
5%
Trifluridine
5%
Tipiracil
5%
Tumor Biology
5%
Gene Fusion
5%
Systemic Therapy
5%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
30%
MicroRNA
21%
Drug Resistance
12%
Capecitabine
12%
Epirubicin
10%
Bevacizumab
10%
Topoisomerase
10%
TOP2A
10%
DNA Topoisomerase
10%
Gene Amplification
10%
Metalloprotease Inhibitor
10%
DNA Methylation
10%
KRAS
10%
MAP2K6
10%
Colon
5%